PARTNERING
Join an elevated partnership
Elevar Therapeutics is dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, as well as expanding access to bring therapies to more patients in more geographies.
Partnership is part of our culture, with highly engaged and diverse teams coming together for a shared purpose: to bring life-changing treatments to more patients.
Elevar is interested in partnerships for the successful development and commercialization of therapies. Click to connect with us.
CURRENT PARTNERSHIPS
A global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody Camrelizumab in combination with Rivoceranib for unresectable hepatocellular carcinoma (uHCC) worldwide, excluding Greater China Region and Korea.
An exclusive global licensing agreement for Lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
ELEVAR CORPORATE PRESENTATION
Interested in partnering with Elevar?
Let’s get in touch
